Are you 65 years of age or older and interested in participating in a clinical study evaluating a new therapy designed to enhance your natural immunity?
What is the study about?
As adults age, there is a decline in immune function which increases the risk of development and/or progression of infections and other diseases. An example of this was demonstrated during the Covid-19 pandemic in which older adults suffered disproportionally.
The RESILIENCE study is evaluating the effectiveness of QBKPN Site-Specific Immunomodulator (SSI) in improving natural immune function and reducing respiratory tract infections in adults 65 years of age or older.
What is QBKPN?
QBKPN is a new medication in a class known as Site-Specific Immunomodulators (SSI). SSIs are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases.
How does the study work?
If you are eligible and want to participate, you will be randomly assigned to QBKPN or placebo, given through a small needle under the skin three times a week for 16 weeks. We will measure your immune function using blood tests over the course of the study, monitor you for infections, and ask you about your quality of life, over a period of a year.
Who is conducting the study?
This study is being conducted by Qu Biologics, which has received funding from the National Research Council of Canada Industrial Research Assistance Program to support the study.
Qu Biologics is a clinical stage biotechnology company based in Burnaby, BC, which is developing the immunomodulatory platform, called Site-Specific Immunomodulators (SSIs.) These are designed to train and/or improve innate immune function to reduce the risk of infections, improve immune response to cancer, and slow the progression of chronic inflammatory diseases.
The study Principal Investigator is Dr. Theodore Steiner, Professor of Medicine at University of British Columbia, Infectious Diseases Specialist at Vancouver General Hospital, Research Scientist at BC Children’s Hospital Research Institute and Chief Medical Officer for Infectious Diseases at Qu Biologics.